Descriptive and prognostic value of patient-reported outcomes: The bortezomib experience in relapsed and refractory multiple myeloma

Journal of Clinical Oncology

Volumn 24, Issue 6, 2006, Pages 976-982

  Dubois, Dominique ^a   Dhawan, Ravinder ^a   van de Velde, Helgi ^a   Esseltine, Dixie ^a   Gupta, Sanjay ^a   Viala, Muriel ^a   de la Loge, Christine ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; FATIGUE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; EUROPE; FEMALE; MALE; MIDDLE AGED; PATIENT SATISFACTION; PREDICTION AND FORECASTING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PATIENT SATISFACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRAZINES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 33644885460     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.0824     Document Type: Article

References (25)

1. Richardson PG, Barlogie B, Berenson J, et al: A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
2. Richardson PG, Briemberg H, Jagannath S, et al: Peripheral neuropathy following bortezomib (VELCADE, formerly PS-341) therapy in patients with advanced multiple myeloma: Characterization and reversibility. Blood 102, 2003 (abstr 512)
3. Richardson PG, Sonneveld P, Schuster M, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
4. Lee SJ, Richardson PG, Sonneveld P, et al: Health-related quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): Results from APEX study. J Clin Oncol 23:568s, 2005 (suppl; abstr 6535)
5. King CR, Haberman M, Berry DL, et al: Quality of life and, the cancer experience: The state of the knowledge. Oncol Nurs Forum 24:27-41, 1997
6. Wisloff F, Eika S, Hippe E, et al: Measurement of health-related quality of life in multiple myeloma: Nordic Myeloma Study Group. Br J Haematol 92:604-613, 1996
7. Gulbrandsen N, Wisloff F, Brinch L, et al: Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 18:65-77, 2001
8. Gulbrandsen N, Hjermstad MJ, Wisløff F: Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 72:172-180, 2004
9. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
10. Osoba D, Zee B, Pater J, et al: Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364, 1994
11. King MT: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555-567, 1996
12. Yellen SB, Cella DF, Webster K, et al: Measuring fatigue and other anaemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63-74, 1997
13. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy (FACT) scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
14. Calhoun EA, Fishman DA, Roland PY, et al: Validity and selective sensitivity of the FACT/GOG-Ntx. Proc Am Soc Clin Oncol 19:446a, 2000 (suppl; abstr 1751)
15. Blade J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma subcommittee of the European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
16. Jaeschke R, Singer J, Guyatt GH: Measurement of health status: Ascertaining the minimal clinically important difference. Control Clin Trials 10:407-415, 1989
17. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
18. Cella DF, Eton DT, Lai JS, et al: Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anaemia and fatigue scales. J Pain Symptom Manage 24:547-561, 2002
19. Cohen J: Statistical Power Analysis for the Behavioural Sciences (ed 8). New York, NY, Academic Press, 1977
20. Greipp PR, San Miguel J, Durie BGM, et al: International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005
21. Fayers P, Weeden S, Curran D: EORTC QLQ-C30 Reference Values. Brussels, Belgium, European Organisation for Research and Treatment of Cancer Quality of Life Study Group, 1998
22. Gunnars B, Nygren P, Glimelius B: Assessment of quality of life during chemotherapy. Acta Oncol 40:175-184, 2001
23. Waldron D, O'Boyle CA, Kearney M, et al: Quality-of-life measurement in advanced cancer: Assessing the individual. J Clin Oncol 17:3603-3611, 1999
24. Flechtner H, Bottomley A: Fatigue assessment in cancer clinical trials. Expert Rev Pharmacoecon Outcomes Res 2:67-76, 2002
25. Dubois D, Dhawan R, van de Velde H, et al: Use of patient-reported outcomes (PRO's) to assess prognosis, toxicity, and response: The bortezomib experience in relapsed and refractory multiple myeloma (MM). Blood 104, 2004 (abstr 3468)